GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (NAS:DOMH) » Definitions » EPS without NRI

Dominari Holdings (Dominari Holdings) EPS without NRI

: $-4.11 (TTM As of Dec. 2023)
View and export this data going back to 1984. Start your Free Trial

Dominari Holdings's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-1.05. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.11.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -0.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 40.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Dominari Holdings's EPS without NRI or its related term are showing as below:

DOMH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -256.7   Med: 10.65   Max: 72.1
Current: -0.4

During the past 13 years, Dominari Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 72.10% per year. The lowest was -256.70% per year. And the median was 10.65% per year.

DOMH's 3-Year EPS without NRI Growth Rate is ranked worse than
56.28% of 1297 companies
in the Biotechnology industry
Industry Median: 4.5 vs DOMH: -0.40

Dominari Holdings's EPS (Diluted) for the three months ended in Dec. 2023 was $-1.29. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.45.

Dominari Holdings's EPS (Basic) for the three months ended in Dec. 2023 was $-1.29. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.45.


Dominari Holdings EPS without NRI Historical Data

The historical data trend for Dominari Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dominari Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.56 -3.99 -1.87 -3.31 -4.03

Dominari Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.70 -1.83 -0.54 -1.05

Competitive Comparison

For the Biotechnology subindustry, Dominari Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dominari Holdings PE Ratio without NRI Distribution

For the Biotechnology industry and Healthcare sector, Dominari Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Dominari Holdings's PE Ratio without NRI falls into.



Dominari Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dominari Holdings  (NAS:DOMH) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Dominari Holdings EPS without NRI Related Terms

Thank you for viewing the detailed overview of Dominari Holdings's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Dominari Holdings (Dominari Holdings) Business Description

Traded in Other Exchanges
Address
One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
Executives
Kyle Michael Wool director 650 5TH AVE, 35TH FLOOR, NEW YORK NY 10019
Christopher Franklin Devall officer: Chief Operating Officer DOMINARI HOLDINGS INC., ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Anthony Hayes director, officer: Chief Executive Officer 1796 SHADY LANE, COLUMBIA SC 29206
George Way officer: Chief Financial Officer C/O DOMINARI HOLDINGS INC., 725 5TH AVENUE 23RD FLOOR, NEW YORK NY 10022
Soo Yu director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Tim S Ledwick director 10200 INNOVATION DRIVE, SUITE 300, MILWAUKEE WI 53226
Gregory James Blattner director ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY 10020
Paul Lemire director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Robert Frederick Dudley director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Zanden Robert J Vander director 913 HIGH KNOLL WAY, TRAVELERS REST SC 29690
Eric Weisblum director 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Howard E Goldberg director 781 THIRD AVENUE, KING OF PRUSSIA PA 194061409
Frank Reiner officer: Interim CFO 6430 ROCKLEDGE DRIVE, SUITE 503, BETHESDA MD 20817
Jeffrey Ballabon director 6430 ROCKLEDGE DRIVE, BETHESDA NY 20817
Richard Cohen officer: Chief Financial Officer C/O DUNE ENERGY, INC., TWO SHELL PLAZA, 777 WALKER STREET, SUITE 2300, HOUSTON TX 77002